Topics

Vaccines against anthrax based on recombinant protective antigen: problems and solutions.

08:00 EDT 12th July 2019 | BioPortfolio

Summary of "Vaccines against anthrax based on recombinant protective antigen: problems and solutions."

Anthrax is a dangerous bio-terror agent because spores are highly resilient and can be easily aerosolized and disseminated. There is a threat of deliberate use of anthrax spores aerosol that could lead to serious fatal diseases outbreaks. Existing control measures against inhalation form of the disease are limited. All of this has provided an impetus to the development of new generation vaccines. Areas сovered: This review is devoted to challenges and achievements in the design of vaccines based on the anthrax recombinant protective antigen (rPA). Scientific databases have been searched, focusing on causes of PA instability and solutions to this problem, including new approaches of rPA expression, novel rPA-based vaccines formulations as well as the simultaneous usage of PA with other anthrax antigens. Expert Opinion: PA is a central anthrax toxin component, playing a key role in the defense against encapsulated and unencapsulated strains. Subunit rPA-based vaccines have a good safety and protective profile. However, there are problems of PA instability that are greatly enhanced when using aluminum adjuvants. New adjuvant compositions, dry formulations and resistant to proteolysis and deamidation mutant PA forms can help to handle this issue. Devising a modern anthrax vaccine requires huge efforts.

Affiliation

Journal Details

This article was published in the following journal.

Name: Expert review of vaccines
ISSN: 1744-8395
Pages:

Links

DeepDyve research library

PubMed Articles [19396 Associated PubMed Articles listed on BioPortfolio]

Self-conjugated protective antigen elicits strong and durable protective antibody response against anthrax.

Anthrax is an acute and highly lethal disease caused by Bacillus anthracis. Protective antigen (PA) is the primary candidate antigen for the anthrax vaccines. However, PA suffers from poor immunogenic...

Cancer-Testis Antigen Peptide Vaccine for Cancer Immunotherapy: Progress and Prospects.

Cancer vaccines, including peptide-based vaccines, have been considered a key tool of effective and protective cancer immunotherapy because of their capacity to provide long-term clinical benefit for ...

Stability of Vaccines.

Vaccines are considered the most economical and effective preventive measure against most deadly infectious diseases. Vaccines help protect around three million lives every year, but hundreds of thous...

Innovative antigen carrier system for the development of tuberculosis vaccines.

A major obstacle to tuberculosis (TB)-subunit-vaccine development has been the induction of inadequate levels of protective immunity due to the limited breadth of antigen in vaccine preparations. In t...

A Tale of Two Mutations: Beginning to Understand the Problems with Egg-Based Influenza Vaccines?

The majority of influenza vaccines are produced in embryonated eggs, but mutations occur as human influenza A(H3N2) viruses adapt to grow in eggs. This can alter virus antigenicity. Wu et al. (2019) ...

Clinical Trials [7496 Associated Clinical Trials listed on BioPortfolio]

Trial to Evaluate the Safety and Immunogenicity of an Anthrax Recombinant Protective Antigen Vaccine

The purpose of this phase 1 study is to evaluate the safety and immunogenicity of rPA102 vaccine, using anthrax vaccine adsorbed (AVA) as a comparator.

A Study of Anthrax Vaccines Px563L and RPA563 in Healthy Adult Subjects

The trial investigates Px563L and RPA563, two formulations of a novel anthrax vaccine.

BARDA Securing Anthrax Immunity For the Elderly

This study is designed to assess the safety and ability of BioThrax and AV7909 anthrax vaccines to generate an immune response in adults ≥ 66 years of age in stable health in comparison ...

A Phase 4 Field Study Evaluating Clinical Benefit and Safety of AIGIV (ANTHRASIL®) in Inhalational Anthrax Patients

This study will evaluate safety and clinical benefit of AIGIV used for treatment of patients with inhalational anthrax. This study will be implemented only in the event of a major anthrax ...

Safety, Tolerability and Immunogenicity of Recombinant Anthrax Vaccine Compared With Anthrax Vaccine Adsorbed

This is a dose ranging study comparing different vaccine schedules of rPA vaccine, for Anthrax, to the licensed dose of AVA, another Anthrax vaccine. Safety and the capability to induce an...

Medical and Biotech [MESH] Definitions

Vaccines or candidate vaccines used to prevent ANTHRAX.

An acute infection caused by the spore-forming bacteria BACILLUS ANTHRACIS. It commonly affects hoofed animals such as sheep and goats. Infection in humans often involves the skin (cutaneous anthrax), the lungs (inhalation anthrax), or the gastrointestinal tract. Anthrax is not contagious and can be treated with antibiotics.

Vaccines using VIROSOMES as the antigen delivery system that stimulates the desired immune response.

ANTHRAX outbreak that occurred in 1979 and was associated with a research facility in Sverdlovsk, in the Ural mountain region of central RUSSIA. Most victims worked or lived in a narrow zone extending from the facility. The zone of anthrax-caused livestock mortality paralleled the northerly wind that prevailed shortly before the outbreak. It was concluded that an escape of ANTHRAX caused outbreak.

Specialized clothing or equipment worn for protection against health hazards. Personal Protective Equipment may include MASKS; RESPIRATORY PROTECTIVE DEVICES; HEAD PROTECTIVE DEVICES; EYE PROTECTIVE DEVICES; EAR PROTECTIVE DEVICES; PROTECTIVE CLOTHING; and protective footwear.

Quick Search


DeepDyve research library

Relevant Topics

Infectious-diseases
Antiretroviral Therapy Clostridium Difficile Ebola HIV & AIDS Infectious Diseases Influenza Malaria Measles Sepsis Swine Flu Tropical Medicine Tuberculosis Infectious diseases are caused by pathogenic...

Recombinant DNA
Recombinant DNA is the formation of a novel DNA sequence by the formation of two DNA strands. These are taken from two different organisms. These recombinant DNA molecules can be made with recombinant DNA technology. The procedure is to cut the DNA of ...

Vaccines
A vaccine is any preparation intended to produce immunity to a disease by stimulating the production of antibodies. It creates immunity but does not cause the disease. There are several differnt types of vaccine avalable; Killed microorganisms; which s...


Searches Linking to this Article